Literature DB >> 10531209

Endothelial adhesion molecule expression and its inhibition by recombinant bactericidal/permeability-increasing protein are influenced by the capsulation and lipooligosaccharide structure of Neisseria meningitidis.

G L Dixon1, R S Heyderman, K Kotovicz, D L Jack, S R Andersen, U Vogel, M Frosch, N Klein.   

Abstract

Vascular endothelial injury is responsible for many of the clinical manifestations of severe meningococcal disease. Binding and migration of activated host inflammatory cells is a central process in vascular damage. The expression and function of adhesion molecules regulate interactions between leukocytes and endothelial cells. Little is known about how meningococci directly influence these receptors. In this study we have explored the effect of Neisseria meningitidis on endothelial adhesion molecule expression and found this organism to be a potent inducer of the adhesion molecules CD62E, ICAM-1, and VCAM-1. Exposure of endothelium to a serogroup B strain of Neisseria meningitidis, B1940, and a range of isogenic mutants revealed that lipooligosaccharide (LOS) structure and capsulation influence the expression of adhesion molecules. Following only a brief exposure (15 min) to the bacteria, there were large differences in the capacity of the different mutants to induce vascular cell adhesion molecules, with the unencapsulated and truncated LOS strains being most potent (P < 0.05). Furthermore, the pattern of cell adhesion molecule expression was different with purified endotoxin from that with intact bacteria. Meningococci were more potent stimuli of CD62E expression than was endotoxin, whereas endotoxin was at least as effective as meningococci in inducing ICAM-1 and VCAM-1. The effect of bactericidal/permeability increasing protein (rBPI(21)), an antibacterial molecule with antiendotoxin properties, was also dependent on LOS structure. The strains which possessed a truncated or nonsialylated LOS, whether capsulated or not, were more sensitive to the inhibitory effects of rBPI(21). These findings could have important implications for the use of antiendotoxin therapy in meningococcal disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10531209      PMCID: PMC96935          DOI: 10.1128/IAI.67.11.5626-5633.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  41 in total

1.  The lipooligosaccharide immunotype as a virulence determinant in Neisseria meningitidis.

Authors:  D M Jones; R Borrow; A J Fox; S Gray; K A Cartwright; J T Poolman
Journal:  Microb Pathog       Date:  1992-09       Impact factor: 3.738

2.  The estimation of the bactericidal power of the blood.

Authors:  A A Miles; S S Misra; J O Irwin
Journal:  J Hyg (Lond)       Date:  1938-11

Review 3.  Pathophysiology, treatment and outcome of meningococcemia: a review and recent experience.

Authors:  E A Kirsch; R P Barton; L Kitchen; B P Giroir
Journal:  Pediatr Infect Dis J       Date:  1996-11       Impact factor: 2.129

4.  Sialic acids of both the capsule and the sialylated lipooligosaccharide of Neisseria meningitis serogroup B are prerequisites for virulence of meningococci in the infant rat.

Authors:  U Vogel; S Hammerschmidt; M Frosch
Journal:  Med Microbiol Immunol       Date:  1996-09       Impact factor: 3.402

5.  Functional characterization of an isogenic meningococcal alpha-2,3-sialyltransferase mutant: the role of lipooligosaccharide sialylation for serum resistance in serogroup B meningococci.

Authors:  U Vogel; H Claus; G Heinze; M Frosch
Journal:  Med Microbiol Immunol       Date:  1997-10       Impact factor: 3.402

6.  Capsule phase variation in Neisseria meningitidis serogroup B by slipped-strand mispairing in the polysialyltransferase gene (siaD): correlation with bacterial invasion and the outbreak of meningococcal disease.

Authors:  S Hammerschmidt; A Müller; H Sillmann; M Mühlenhoff; R Borrow; A Fox; J van Putten; W D Zollinger; R Gerardy-Schahn; M Frosch
Journal:  Mol Microbiol       Date:  1996-06       Impact factor: 3.501

7.  Invasion of human mucosal epithelial cells by Neisseria gonorrhoeae upregulates expression of intercellular adhesion molecule 1 (ICAM-1).

Authors:  G A Jarvis; J Li; K V Swanson
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

8.  Meningococcal Opa and Opc proteins: their role in colonization and invasion of human epithelial and endothelial cells.

Authors:  M Virji; K Makepeace; D J Ferguson; M Achtman; E R Moxon
Journal:  Mol Microbiol       Date:  1993-11       Impact factor: 3.501

9.  Bactericidal/permeability-increasing protein protects vascular endothelial cells from lipopolysaccharide-induced activation and injury.

Authors:  M Arditi; J Zhou; S H Huang; P M Luckett; M N Marra; K S Kim
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

10.  Activation and homologous desensitization of human endothelial cells by CD40 ligand, tumor necrosis factor, and interleukin 1.

Authors:  K Karmann; W Min; W C Fanslow; J S Pober
Journal:  J Exp Med       Date:  1996-07-01       Impact factor: 14.307

View more
  15 in total

1.  Analysis of pathogen-host cell interactions in purpura fulminans: expression of capsule, type IV pili, and PorA by Neisseria meningitidis in vivo.

Authors:  O B Harrison; B D Robertson; S N Faust; M A Jepson; R D Goldin; M Levin; R S Heyderman
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

2.  Dendritic cell activation and cytokine production induced by group B Neisseria meningitidis: interleukin-12 production depends on lipopolysaccharide expression in intact bacteria.

Authors:  G L Dixon; P J Newton; B M Chain; D Katz; S R Andersen; S Wong; P van der Ley; N Klein; R E Callard
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

Review 3.  Rationale for Adjunctive Therapies for Pediatric Sepsis Induced Multiple Organ Failure.

Authors:  Bradley S Podd; Dennis W Simon; Santiago Lopez; Andrew Nowalk; Rajesh Aneja; Joseph A Carcillo
Journal:  Pediatr Clin North Am       Date:  2017-08-18       Impact factor: 3.278

4.  Differential gene expression during meningeal-meningococcal interaction: evidence for self-defense and early release of cytokines and chemokines.

Authors:  D B Wells; P J Tighe; K G Wooldridge; K Robinson; D A Ala' Aldeen
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

5.  Gene expression pattern in human brain endothelial cells in response to Neisseria meningitidis.

Authors:  Alexandra Schubert-Unkmeir; Olga Sokolova; Ursula Panzner; Martin Eigenthaler; Matthias Frosch
Journal:  Infect Immun       Date:  2006-11-27       Impact factor: 3.441

6.  Gram-negative bacteria induce proinflammatory cytokine production by monocytes in the absence of lipopolysaccharide (LPS).

Authors:  H Uronen; A J Williams; G Dixon; S R Andersen; P Van Der Ley; M Van Deuren; R E Callard; N Klein
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

7.  The diabetic ocular environment facilitates the development of endogenous bacterial endophthalmitis.

Authors:  Phillip S Coburn; Brandt J Wiskur; Elizabeth Christy; Michelle C Callegan
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-11-01       Impact factor: 4.799

8.  High-level endothelial E-selectin (CD62E) cell adhesion molecule expression by a lipopolysaccharide-deficient strain of Neisseria meningitidis despite poor activation of NF-kappaB transcription factor.

Authors:  G L J Dixon; R S Heyderman; P van der Ley; N J Klein
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

9.  Activation of toll-like receptor 2 (TLR2) and TLR4/MD2 by Neisseria is independent of capsule and lipooligosaccharide (LOS) sialylation but varies widely among LOS from different strains.

Authors:  Alison C Pridmore; Gary A Jarvis; Constance M John; Dominic L Jack; Steven K Dower; Robert C Read
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

10.  Up-regulation of ICAM-1, CD11a/CD18 and CD11c/CD18 on human THP-1 monocytes stimulated by Streptococcus suis serotype 2.

Authors:  D Al-Numani; M Segura; M Doré; M Gottschalk
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.